AstraZeneca gets US FTC nod for $39bn Alexion acquisition
AstraZeneca has initially announced the acquisition of the US-based pharmaceutical firm for a total consideration of $39bn in…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
19 Apr 21
AstraZeneca has initially announced the acquisition of the US-based pharmaceutical firm for a total consideration of $39bn in…
19 Apr 21
The FDA approval is based on CheckMate-649, a Phase 3 trial evaluating Opdivo in combination with chemotherapy
15 Apr 21
The Chinese regulatory approval is based on positive results from the Phase 3 ADAURA trial, which enrolled 682…
15 Apr 21
The EC approval is based on results from the CheckMate -9ER an open-label, randomised, Phase 3 clinical trial…
14 Apr 21
The company has partnered with the Russian Direct Investment Fund (RDIF) in September last year for clinical trials…
14 Apr 21
CDC and FDA are reviewing data comprising six cases of a rare and severe type of blood clot…
31 Mar 21
The approval is based on two Phase 3 ASCLEPIOS studies, which met the primary endpoints of reduction in…
29 Mar 21
VIR-7831 is an investigational dual-action SARS-CoV-2 monoclonal antibody intended for treating mild-to-moderate Covid-19
26 Mar 21
Breyanzi is a chimeric antigen receptor (CAR) T cell therapy designed to target CD19, a biomarker for normal…
22 Mar 21
Ponvory is a once-daily oral selective sphingosine-1-phosphate receptor 1 (S1P1) modulator that keeps lymphocytes out of the blood